The positivity rates of a novel test in the patients with suspected clostridioides difficile associated diarrhea

Aim: To evaluate the positivity rates of Clostridioides difficile infection (CDI) in the stool samples with a novel test and clinicalfeatures of positive cases.Material and Methods: The frequency of C. difficile in a total of 654 stool samples were examined with the BD Max Cdiff Test (BectonDickinson, USA) between January 2014 and June 2019, and the clinical/demographic characteristics of the positive cases wereevaluated in a university hospital.Results: A total 56 (8.56%) samples belonging to 49 cases aged 3-84 year were determined as positive for CDI among total 654 stool samples.Forty-one (89.1%) out of 46 positive cases whose clinical reports were available had a history of hospitalization in the last three monthswith an average 14.9 days, and 39 patients (84.7%) received antimicrobial treatment in the last three months for an average 12.2 days. It wasobserved that 40 (86.9%) out of 46 positive cases had at least one underlying chronic disease; and 38 (82.6%) patients used anti-acid agents.Conclusion: In this study, although the risk factors similar to those reported in the international literature were also found for ourpatients, the incidence of CDI was found to be lower than that reported worldwide. In this context, it is required that the patients inthe risk group for CDI must be identified well, and correct and fast methods should be used for diagnosing the infection.

PDF

___

1. Sandlund J, Bartolome A, Almazan A, et al. Ultrasensitive detection of Clostridioides difficile Toxins A and B by use of automated single-molecule counting technology. J Clin Microbiol 2018;56:00908- 18.
2. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011;365:1693-703.
3. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:987-94.
4. Fang FC, Polage CR, Wilcox MH. Point-counterpoint: what is the optimal approach for detection of Clostridium difficile infection? J Clin Microbiol 2017;55:670-80.
5. Le Guern R, Herwegh S, Grandbastien B, et al. Evaluation of a new molecular test, the BD Max Cdiff, for detection of toxigenic Clostridium difficile in fecal samples. J Clin Microbiol 2012;50:3089-3090.
6. Aygün G, Aslan M, Yaşar H, et al. Antibiyotikle ilişkili ishal olgularında Clostridium difficile Toksin A+B araştırılması. Türk Mikrobiyol Cem Derg 2003;33:39- 41.
7. Lale Z, Doğruman Al F, Fidan I, et al. İshalli hastaların dışkı örneklerinde Clostridium difficile toksin A/B sıklığının araştırılması. ANKEM Derg 2013;27:55-9.
8. Kostul H, Delialioğlu N, Horasan EŞ, et al. Hastanede yatan hastaların dışkı örneklerinde Clostridium difficile toksin araştırılması ve risk faktörlerinin incelenmesi. Turk Hij Den Biyol Derg 2015;72:183-90.
9. Ünlü O, Cicek C, Filcan A, et al. Bir üniversite hastanesine başvuran hastalarda gastroenterit etkenlerinin dağılımı: on üç aylık veriler. Turk Mikrobiyol Cem Derg 2013;43:149-54.
10. Gateau C, Couturier J, Coia J, et al. How to: diagnose infection caused by Clostridium difficile. Clin Microbiol Infect 2018;24:463-8.
11. Morinaga Y, Akamatsu N, Matsuda J, et al. Diagnostic utilities of a fully automated molecular test for toxigenic Clostridium difficile. J Infect Chemother 2018;24:88-91.
12. Benson L, Song X, Campos J, et al. Changing epidemiology of Clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol 2007;28:1233-5.
13. Deniz U, Ülger N, Aksu B, et al. Marmara Üniversitesi Hastanesinde yatan ishalli hastalardan izole edilen Clostridium difficile kökenlerinde toksin genlerinin araştırılması. Mikrobiyol Bul 2011;45:1-10.
14. Privitera G, Scarpellini P, Ortisi G, et al. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother 1991;35:208-10.
15. Donnelly JP, Wang HE, Locke JE, et al. Hospital-onset Clostridium difficile infection among solid organ transplant recipients. Am J Transplant 2015;15:2970- 7.
16. Paudel S, Zacharioudakis IM, Zervou FN, et al. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS One 2015;10:0124483.
17. Phatharacharukul P, Thongprayoon C, Cheungpasitporn W, et al. The risks of incident and recurrent Clostridium difficile-associated diarrhea in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis. Dig Dis Sci 2015;60:2913–22.
18. İris NE, Demirel A, Koçulu S, et al. Diyaresi olan febril nötropenik hastalarda Clostridium difficile Toksin A ve B pozitifliği oranları ve epidemiyolojik özelliklerinin değerlendirilmesi. Mediterr J Infect Microb Antimicrob 2015;4:14.
19. Novack L, Kogan S, Gimpelevich L, et al. Acid suppression therapy does not predispose to Clostridium difficile infection: the case of the potential bias. PLoS One 2014;9:110790.
20. Buccigrossi V, Lo Vecchio A , Marano A, et al. Differential effects of Clostridium difficile toxins on ion secretion and cell integrity in human intestinal cells. Pediatric Research 2019;85:1048-54.